Menovo Pharmaceutical's shares hit the daily limit after it disclosed its 2026 half-year report. In the first half of the year, the company achieved operating revenue of 859 million yuan, up 26.79% year-on-year, and net profit attributable to the parent company of 63.6891 million yuan, up 29.83% year-on-year. In the second quarter, foreign investors including UBS Group, Morgan Stanley, and Barclays Bank became new top-ten shareholders, while Hong Kong Securities Clearing Company increased its holdings to become the second-largest shareholder. Internet-famous retail investor 'Xin Duoduo' Liu Xin became a new fourth-largest shareholder. Menovo Pharmaceutical specializes in specialty active pharmaceutical ingredients and formulations, and is one of the Chinese companies exporting the most varieties of specialty APIs to Europe.
Ningbo Menovo Pharm Co LtdHalf-year net profit up 29.83% and revenue up 26.79%, driving shares to daily limit.
